Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 201Recurrence 52Neoplasms, Plasma Cell 19Neoplasms 13Immunoglobulin Light-chain Amyloidosis 10Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Myeloproliferative Disorders 4Lymphoma, B-Cell 4Hematologic Diseases 4Amyloidosis 4Waldenstrom Macroglobulinemia 3Sarcoma, Kaposi 3Renal Insufficiency 3Primary Myelofibrosis 3Polycythemia Vera 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Burkitt Lymphoma 3Blood Protein Disorders 3Plasmacytoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Lymphoma, Follicular 2Disease Progression 2Chromosome 17 deletion 2Central Nervous System Neoplasms 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1

Interventions

Rituximab 17Peripheral Blood Stem Cell Transplantation 15Cyclophosphamide 15fludarabine phosphate 12Whole-Body Irradiation 11Cyclosporine 10Mycophenolic Acid 9Etoposide 9Methotrexate 8Filgrastim 8Lenalidomide 7Tacrolimus 6Dexamethasone 6Busulfan 6Radiotherapy 5Melphalan 5Cytarabine 5Carboplatin 5Vorinostat 4Thiotepa 4Therapeutics 4Psychiatric Rehabilitation 4Bortezomib 4Antilymphocyte Serum 4Transplantation 3Methylprednisolone 3Irinotecan 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Dasatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intraocular Lymphoma × pomalidomide × Clear all
NCT01722305 2019-07-22

Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

Mayo Clinic

Phase 1 Completed
29 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡